Bristol-Myers: Q4 exceeds expectations
(CercleFinance.com) - Bristol-Myers Squibb has reported a net loss of 1.
42 dollar per share for the last three months of 2017, weighed on by costs relating to the US tax reforms.
In adjusted terms, however, EPS rose 8% to 68 cents, one cent above the consensus.
The pharmaceutical company's revenues increased by 4% to over 5.4 billion dollars (+2% excluding FX factors), in particular boosted by the strong sales of its anti-cancer drug Opdivo and its anticoagulant Eliquis.
With adjusted FY EPS that is up 6% at 3.01 dollars, in line with its end-of-October target range (2.95 dollars to 3.05 dollars), Bristol-Myers Squibb expects FY 2018 EPS of between 3.15 dollars and 3.30 dollars.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
42 dollar per share for the last three months of 2017, weighed on by costs relating to the US tax reforms.
In adjusted terms, however, EPS rose 8% to 68 cents, one cent above the consensus.
The pharmaceutical company's revenues increased by 4% to over 5.4 billion dollars (+2% excluding FX factors), in particular boosted by the strong sales of its anti-cancer drug Opdivo and its anticoagulant Eliquis.
With adjusted FY EPS that is up 6% at 3.01 dollars, in line with its end-of-October target range (2.95 dollars to 3.05 dollars), Bristol-Myers Squibb expects FY 2018 EPS of between 3.15 dollars and 3.30 dollars.
Copyright (c) 2018 CercleFinance.com. All rights reserved.